Every round on record, with the sources behind each and the investors on them.
A privately held clinical-stage company developing CAR-T therapies
avencell.comLinkedIn500 Forge Road, Watertown, MA 02472, USABiotechFounded 202165 people
3 sources · checked 1 time, last 2h ago
The sources describe a broader financing agreement of up to $47 million, including up to $41 million in royalty financing; that figure is not the Series C amount.
1 source
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series C | $6M | 2026-09-24 | not stated | 3 outlets. #47 in Trending |
3 sources · checked 1 time, last 2h ago [ VERIFIED · CORRECTED ] read against 3 sources
The sources describe a broader financing agreement of up to $47 million, including up to $41 million in royalty financing; that figure is not the Series C amount. | ||||
AvenCell develops switchable, autologous and allogeneic CAR-T immunotherapies for people with hard-to-treat cancers and autoimmune diseases.
Checked against 8 sources today
| Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $112M | 2024-10-22 | Novo Holdings | No recent discussion |
1 source [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: prnewswire.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ ALEXANDRIA ]firmographics from FullEnrich via Alexandria·[ AGENT ]company research by the Firecrawl agent | ||||
Via Alexandria from FullEnrich: type, industry
Also named as backers in company research: Japan Agency for Medical Research and Development (AMED), SAB Sächsische Aufbaubank-Förderbank, European Union/ European Social Fund, Federal Ministry of Education and Research